ImmunoPrecise Antibodies Ltd.
IPA
$0.4071
-$0.0308-7.03%
NASDAQ
| 01/31/2025 | 10/31/2024 | 07/31/2024 | 04/30/2024 | 01/31/2024 | |
|---|---|---|---|---|---|
| Net Income | -228.82% | -72.90% | -30.09% | 2.34% | 49.38% |
| Total Depreciation and Amortization | 19.77% | 10.70% | 7.02% | 7.59% | 13.92% |
| Total Amortization of Deferred Charges | -94.15% | -95.31% | -96.51% | -97.65% | -12.76% |
| Total Other Non-Cash Items | 906.20% | 257.70% | 267.64% | 324.23% | 372.91% |
| Change in Net Operating Assets | -3.21% | 195.49% | 641.94% | 170.12% | 34.57% |
| Cash from Operations | -103.02% | -20.81% | 45.93% | 79.21% | 80.89% |
| Capital Expenditure | -112.38% | -12.19% | 2.56% | 7.78% | 39.10% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | 100.00% | 100.00% | 100.00% | 75.42% | 97.15% |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | 145.56% | -200.00% | -150.62% | -115.67% | 77.36% |
| Cash from Investing | -71.51% | -16.41% | 22.72% | 21.62% | 84.85% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -1.76% | 3.46% | 9.72% | -0.15% | -16.79% |
| Issuance of Common Stock | 1,356.84% | 3,845.92% | 377.55% | 229.61% | -76.84% |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | -- |
| Cash from Financing | 3,366.40% | 566.14% | 566.17% | 261.99% | -116.07% |
| Foreign Exchange rate Adjustments | -380.71% | 204.70% | -58.35% | -104.96% | -82.00% |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 222.13% | 72.70% | 77.74% | 78.35% | 77.18% |